GH - Guardant Health, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Redwood City,
United States
Type: Equity
GH price evolution
GH
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1035.24 | $1129.26 | $1133.54 | |
| Short term investments | $35.1 | |||
| Net receivables | $88.47 | $100.52 | $84.56 | $88.78 |
| Inventory | $72.3 | $66.98 | $62.99 | $61.95 |
| Total current assets | $1226.71 | $1289.97 | $1308.55 | $1347.11 |
| Long term investments | ||||
| Property, plant & equipment | $270.13 | $278.43 | $290.27 | $302.71 |
| Goodwill & intangible assets | $11.03 | $11.58 | $12.27 | |
| Total noncurrent assets | $319.37 | $396.05 | $439.31 | |
| Total investments | $35.1 | |||
| Total assets | $1538.73 | $1609.34 | $1704.6 | $1786.42 |
| Current liabilities | ||||
| Accounts payable | $15.47 | $42.45 | $37.6 | $187.95 |
| Deferred revenue | $29.38 | $22.56 | $17.96 | |
| Short long term debt | ||||
| Total current liabilities | $197.34 | $201.57 | $220.01 | $205.92 |
| Long term debt | $1141.9 | $1313.45 | $1140.61 | $1325.81 |
| Total noncurrent liabilities | $1409.38 | $1416.3 | $1421.82 | |
| Total debt | $1313.45 | $1319.52 | $1325.81 | |
| Total liabilities | $1598.82 | $1610.95 | $1636.31 | $1627.74 |
| Shareholders' equity | ||||
| Retained earnings | -$2467.23 | -$2359.47 | -$2256.85 | -$2141.86 |
| Other shareholder equity | -$5.64 | -$4.8 | -$3.67 | |
| Total shareholder equity | -$1.61 | $68.28 | $158.68 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1133.54 | $141.65 | $492.2 | $832.98 |
| Short term investments | $35.1 | $869.58 | $440.55 | $961.9 |
| Net receivables | $88.78 | $97.26 | $97.65 | $53.3 |
| Inventory | $61.95 | $51.6 | $30.67 | $22.72 |
| Total current assets | $1347.11 | $1191.59 | $1114.13 | $1888.36 |
| Long term investments | $698.03 | $246.6 | ||
| Property, plant & equipment | $302.71 | $341.92 | $313.9 | $100.13 |
| Goodwill & intangible assets | $12.27 | $15.02 | $17.5 | $19.49 |
| Total noncurrent assets | $439.31 | $418.39 | $1090.37 | $383.42 |
| Total investments | $35.1 | $869.58 | $1138.58 | $1208.5 |
| Total assets | $1786.42 | $1609.98 | $2204.5 | $2271.78 |
| Current liabilities | ||||
| Accounts payable | $187.95 | $68.91 | $17.58 | $7.34 |
| Deferred revenue | $17.96 | $17.4 | $11.33 | $8.55 |
| Short long term debt | ||||
| Total current liabilities | $205.92 | $193.22 | $194.69 | $66.81 |
| Long term debt | $1325.81 | $1137.39 | $1360.87 | $847.86 |
| Total noncurrent liabilities | $1421.82 | $1356.59 | $1364.81 | $849.38 |
| Total debt | $1325.81 | $1347.41 | $1360.87 | $847.86 |
| Total liabilities | $1627.74 | $1549.81 | $1559.49 | $916.19 |
| Shareholders' equity | ||||
| Retained earnings | -$2141.86 | -$1662.41 | -$1007.83 | -$606.59 |
| Other shareholder equity | -$3.67 | -$19.52 | -$4.76 | $2.7 |
| Total shareholder equity | $158.68 | $60.18 | $645 | $1298.49 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $177.24 | $168.49 | $155.05 | |
| Cost of revenue | $72.42 | $65.3 | $62.52 | |
| Gross Profit | $104.81 | $103.19 | $92.54 | |
| Operating activities | ||||
| Research & development | $83.1 | $83.8 | $89.86 | |
| Selling, general & administrative | $122.33 | $119.08 | $116.79 | |
| Total operating expenses | $205.43 | $202.88 | $290.05 | |
| Operating income | -$100.62 | -$99.68 | -$197.51 | |
| Income from continuing operations | ||||
| EBIT | -$101.85 | -$113.94 | -$186.94 | |
| Income tax expense | $0.13 | $0.41 | -$0.54 | |
| Interest expense | $0.65 | $0.65 | $0.65 | |
| Net income | ||||
| Net income | -$102.63 | -$114.98 | -$187.04 | |
| Income (for common shares) | -$102.63 | -$114.98 | -$187.04 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $563.95 | $449.54 | $373.65 | $286.73 |
| Cost of revenue | $227.05 | $156.32 | $122.91 | $92.53 |
| Gross Profit | $336.9 | $293.21 | $250.74 | $194.19 |
| Operating activities | ||||
| Research & development | $367.19 | $373.81 | $263.22 | $149.86 |
| Selling, general & administrative | $451.03 | $463.78 | $398.52 | $299.28 |
| Total operating expenses | $901.62 | $837.59 | $661.74 | $449.14 |
| Operating income | -$564.73 | -$544.38 | -$411 | -$254.95 |
| Income from continuing operations | ||||
| EBIT | -$476.19 | -$650.87 | -$402.79 | -$248.64 |
| Income tax expense | $0.69 | $1.14 | $0.3 | $0.38 |
| Interest expense | $2.58 | $2.58 | $2.58 | $4.77 |
| Net income | ||||
| Net income | -$479.45 | -$654.59 | -$405.67 | -$253.78 |
| Income (for common shares) | -$479.45 | -$654.59 | -$405.67 | -$253.78 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$102.63 | -$114.98 | -$187.04 | |
| Operating activities | ||||
| Depreciation | $10.62 | $10.71 | $10.87 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $27.23 | $27.04 | $24.32 | |
| Total cash flows from operations | -$94 | -$30.28 | -$78.73 | |
| Investing activities | ||||
| Capital expenditures | -$5.08 | -$6.93 | -$4.08 | |
| Investments | $35 | $666 | ||
| Total cash flows from investing | -$271.84 | -$5.08 | $28.07 | $663.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $9.58 | $0.21 | $114.67 | |
| Net borrowings | ||||
| Total cash flows from financing | $1.94 | $5.9 | -$1.07 | $90.57 |
| Effect of exchange rate | -$0.07 | -$0.84 | -$1.14 | $1.03 |
| Change in cash and equivalents | -$445.32 | -$94.02 | -$4.43 | $676.32 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$479.45 | -$654.59 | -$405.67 | -$253.78 |
| Operating activities | ||||
| Depreciation | $42.88 | $64.55 | $46.93 | $21.63 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $90.76 | $94.69 | $151.45 | $144.11 |
| Total cash flows from operations | -$324.98 | -$309.46 | -$209.02 | -$103.93 |
| Investing activities | ||||
| Capital expenditures | -$20.49 | -$77.46 | -$75.03 | -$54.06 |
| Investments | $859.21 | $227.28 | $11.88 | -$563.03 |
| Total cash flows from investing | $840.25 | $149.82 | -$63.16 | -$617.09 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $503.68 | $11.94 | $17.86 | $371.22 |
| Net borrowings | -$0.07 | -$0.93 | $1132.58 | |
| Total cash flows from financing | $477.38 | -$189.09 | -$66.82 | $1410.31 |
| Effect of exchange rate | -$0.91 | -$1.6 | -$1.69 | $0.46 |
| Change in cash and equivalents | $991.74 | -$350.34 | -$340.69 | $689.75 |
News
Fundamentals
| Market cap | $11.38B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 123.16M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 10.26 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.22 |
| Quick ratio | 5.85 |